GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (STU:1NE) » Definitions » Gross Margin %

Verrica Pharmaceuticals (STU:1NE) Gross Margin % : 70.26% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Verrica Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Verrica Pharmaceuticals's Gross Profit for the three months ended in Mar. 2024 was €2.47 Mil. Verrica Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was €3.52 Mil. Therefore, Verrica Pharmaceuticals's Gross Margin % for the quarter that ended in Mar. 2024 was 70.26%.


The historical rank and industry rank for Verrica Pharmaceuticals's Gross Margin % or its related term are showing as below:

STU:1NE' s Gross Margin % Range Over the Past 10 Years
Min: 79.63   Med: 88.71   Max: 91.97
Current: 79.63


During the past 8 years, the highest Gross Margin % of Verrica Pharmaceuticals was 91.97%. The lowest was 79.63%. And the median was 88.71%.

STU:1NE's Gross Margin % is ranked better than
74.27% of 750 companies
in the Biotechnology industry
Industry Median: 60.53 vs STU:1NE: 79.63

Verrica Pharmaceuticals had a gross margin of 70.26% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Verrica Pharmaceuticals was 0.00% per year.


Verrica Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Verrica Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Gross Margin % Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial - - - 91.98 85.44

Verrica Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.86 25.00 90.74 86.34 70.26

Competitive Comparison of Verrica Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Verrica Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verrica Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's Gross Margin % falls into.



Verrica Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Verrica Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=4 / 4.699
=(Revenue - Cost of Goods Sold) / Revenue
=(4.699 - 0.684) / 4.699
=85.44 %

Verrica Pharmaceuticals's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=2.5 / 3.52
=(Revenue - Cost of Goods Sold) / Revenue
=(3.52 - 1.047) / 3.52
=70.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Verrica Pharmaceuticals  (STU:1NE) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Verrica Pharmaceuticals had a gross margin of 70.26% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Verrica Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verrica Pharmaceuticals (STU:1NE) Business Description

Traded in Other Exchanges
Address
44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals (STU:1NE) Headlines

No Headlines